Long-Term Safety And Tolerability Of Nktr-181 In Patients With Moderate To Severe Chronic Low Back Pain Or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (Summit-08 Lts)

Objective. To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP). Design. Uncontrolled, multicenter, open-label, long-term study of NKTR-181 comprised of three periods: screening (<21 days), treatment (52 weeks), and safety follow-up (similar to 14 days after the last dose of NKTR-181). Setting. Multicenter, long-term clinical research study. Methods. NKTR-181 administered at doses of 100-600 mg twice daily (BID) was evaluated in opioid-naive and opioid-experienced patients. Patients were enrolled de novo or following completion of the randomized, placebo-controlled phase 3 efficacy study (SUMMIT-07). Safety assessments included adverse event documentation, measurements of opioid withdrawal, and clinical laboratory tests. Effectiveness was assessed using the modified Brief Pain Inventory Short Form (mBPI-SF). Results. The study enrolled 638 patients. The most frequently reported treatment-emergent adverse events (TEAEs) were constipation (26%) and nausea (12%). Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181. There were no deaths or reported cases of respiratory depression. A sustained reduction in mBPI-SF pain intensity and pain interference from baseline to study termination was observed throughout treatment. Only 2% of patients discontinued NKTR-181 due to lack of efficacy, and 11% discontinued due to treatment-related AEs. NKTR-181 doses of up to 600 mg BID were generally well tolerated, and patients experienced low rates of opioid-related adverse events. Conclusions. The study results support the premise that NKTR-181 is a safe and effective option for patients with moderate to severe CLBP or CNP.